Archive: Company News
Company News: ISA Pharmaceuticals Further Strengthens IP Position on Lead Compound ISA101
– Three additional European patents and market exclusivity granted for the use of key active ingredients of ISA101
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has strengthened the IP position of its lead compound ISA101. The European Patent Office has granted three patents (EP2267132, EP2112157, EP2468763) which relate to the use of HPV antigen-based peptides. ISA101, a novel immunotherapeutic consisting of synthetic long peptides (SLP®s), targets severe diseases triggered by human papillomavirus (HPV) infection.
The patents cover the application of a variety of long peptides derived from the E6 and E7 proteins of HPV, including novel epitopes or peptides with specified features, and provide exclusivity for the treatment of persistent HPV infections and resulting diseases.
ISA101 is based on ISA Pharmaceuticals´ proprietary SLP® platform and is currently in clinical Phase I/II trials in cervical cancer and anal intraepithelial neoplasia (AIN).
Company News: Lead Pharma Appoints Three Seasoned Industry Experts to its Supervisory Board
– Jan Egberts, M.D., Ir. Jan van der Hoeven and Daan van den Noort, M.D. join newly established Supervisory Board
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has appointed Dr. Jan Egberts, Ir. Jan van der Hoeven and Daan van den Noort to its newly established Supervisory Board.
Jan Egberts, M.D., has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer of Agendia Inc., a molecular diagnostics company. Prior to this, Dr. Egberts was Chief Executive Officer of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013. He also served as a Senior Healthcare Advisor for 3i Group plc and as President, Chairman and Chief Executive Officer of NovaDel Pharmaceuticals Inc. In addition, he held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care. Dr. Egberts, who graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, also serves on the Supervisory Board of several other private and public healthcare companies.
Ir. Jan van der Hoeven brings more than 30 years of experience in the biopharmaceutical industry. In 1983, he was co-founder of the CRO NOTOX, which he also headed until it was acquired by WIL Research Laboratories in 2006. In addition, since 1988 he has advised numerous life sciences companies, e.g. as a member of the Supervisory Board. He is also an ambassador of Wageningen University (Wageningen, The Netherlands). Before founding NOTOX, he worked as a scientist at Wageningen University for six years with emphasis on the relation of food and cancer. He (co-)authored over 30 scientific publications and has been awarded the EEMS Young Scientist Award in 1985. In 2003, he received the price for entrepreneurship from Wageningen University. Ir. van der Hoeven graduated from Wageningen University.
Daan van den Noort, M.D., brings over 25 years of experience as a manager and venture capitalist in the pharmaceutical and biotechnology industry in Europe. Among others, he served as General Manager for Genentech, Asta Medica, and Ferring in The Netherlands. From 2001 to 2011, he acted as the Chief investment Officer of the Biotech Turnaround Fund. He serves on several international boards of investment companies active in the biopharmaceutical industry. Mr. van den Noort holds an MD degree from the Free University of Amsterdam.
Company News: Humabs BioMed Reports Clinical Milestone in Antibody Licensing Agreement
Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that it has received a milestone payment from its licensing agreement with Novartis. In 2009, Humabs and Novartis entered into an exclusive licensing agreement for the use of selective human monoclonal antibodies discovered by Humabs’ proprietary Cellclone technology. A Novartis program based on this technology has entered into phase II clinical trials in the U.S. and Germany, triggering the payment.
“We are very pleased about reaching this important milestone,” said Alcide Barberis, CEO of Humabs BioMed. “This underlines the value of our platform, which is not just selecting for binders to pre-defined targets, but uses a functional, target-agnostic approach.”
Company News: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10, 2015). All posters will focus on Anergis´ birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis´ most advanced product and based on the company´s proprietary Contiguous Overlapping Peptide (COP) platform.
The following scientific communications will be presented at the EAACI Conference 2015:
Presentation Title: “Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season”
Presenter: Gilles Della Corte
Time and Date: Sunday, June 7, 2015, at 02:06pm CET
Session: Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes
Abstract #: 327
Presentation Title: “Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)”
Presenter: Dr. Christophe Reymond
Time and Date: Tuesday, June 9, 2015, at 10:30am CET
Session: Poster Discussion Session PDS 25: Immunotherapy vaccines
Abstract #: 530
Presentation Title: “Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT”
Presenter: Dr. Alexander Kettner
Time and Date: Monday, June 8, 2015, at 12:00pm CET
Session: Thematic Poster Session TPS 32: Allergen standardization
Abstract #: 1141